Zacks Small Cap Estimates Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for Cytosorbents in a report issued on Friday, April 4th. Zacks Small Cap analyst T. Kerr forecasts that the medical research company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents’ Q2 2025 earnings at ($0.06) EPS.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

A number of other equities analysts have also recently commented on CTSO. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a report on Tuesday, April 1st. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Thursday. They set a “hold” rating for the company. Finally, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Thursday. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Trading Down 2.0 %

Shares of NASDAQ CTSO opened at $0.97 on Monday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The business’s 50 day moving average is $1.07 and its two-hundred day moving average is $1.04. The stock has a market capitalization of $60.63 million, a P/E ratio of -2.69 and a beta of 1.17.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently modified their holdings of CTSO. Avenir Corp increased its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares during the period. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Geode Capital Management LLC increased its stake in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the period. Raymond James Financial Inc. bought a new stake in Cytosorbents during the 4th quarter valued at about $99,000. Finally, Northern Trust Corp boosted its position in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.